Comparative Efficacy Of Ketorol Dt V/S Chymoral Forte Medications In Impacted Mandibular Third Molar Surgeries – A Prospective Study

Abstract

Aims & Background: This study's objective was to assess the efficacy of of an enzyme preparation called Chymoral Forte and an NSAID called Ketorol-DT in treating trismus, oedema, and pain after surgery on impacted mandibular third molars.

Materials and Methods: 30 individuals undergoing impacted mandibular third molar extractions participated in this clinical trial that is randomised. Two groups of patients were formed: Group B (n=15) received Chymoral Forte (100,000 IU of trypsin and chymotrypsin) twice daily for seven days, while Group A (n=15) received Ketorol-DT (10 mg) every six hours for 24 hours following surgery. On Days 1, 3, and 7, the Visual Analogue Scale (VAS), measurements of the face, and measurements of the mouth opening were used to evaluate the patient's pain, oedema, and trismus.

Results: With a mean VAS score of 7.00 against 8.33 for Chymoral Forte, Ketorol-DT demonstrated superior pain reduction effectiveness. However, Chymoral Forte produced marginally better mouth opening (mean: 34.20 mm vs. 31.07 mm) and improved patient satisfaction (mean: 8.73 vs. 7.60). Postoperative oedema was considerably decreased by ketorol-DT (p=0.018).

Conclusion: While Chymoral Forte is less effective for pain but enhances patient satisfaction and recovery, Ketorol-DT is more effective for providing rapid pain relief and reducing oedema. A combination of the two could provide thorough postoperative care.

Clinical significance: For the management of pain and oedema, ketorol-DT is the better option, although chymoral forte improves patient satisfaction and healing in general.